MedTrace Logo

Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy

NCT01902875 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-07-18

No results posted yet for this study

Summary

This clinical Trial is proposed to explore whether preconditioning chemotherapy of Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy could benefit NSCLC patients with a better clinical outcome.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Paclitaxel + Cisplatin

Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.

BIOLOGICAL

CIK cell therapy

Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).

Sponsors & Collaborators

  • Jinling Hospital, China

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01902875 on ClinicalTrials.gov